- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Participating Faculty: Expenditures for Medicaid Patients Treated With Exenatide Compared With Other Diabetes Management Regimens
The American Journal of Managed Care
This supplement to reports results from a retrospective cohort analysis of Medicaid claims data designed to compare Medicaid spending among patients with type 2 diabetes mellitus receiving exenatide, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, or basal insulin as add-on antidiabetic therapy. It also discusses the implications and limitations of these study results.This supplement was supported by Amylin Pharmaceuticals, Inc.
FacultyJennie H. Best, PhD
Director, Health Economics and Outcomes Research
Medical Research and Development
Amylin Pharmaceuticals, Inc
San Diego, California
Ryan M. Conrad, PhD
Economist
Precision Health Economics, LLC
Los Angeles, California
Dana P. Goldman, PhD
Norman Topping Chair in Medicine and Public Policy
Price School of Public Policy
Director
Leonard D. Schaeffer Center for Health Policy and Economics
University of Southern California
Los Angeles, California
Anne L. Peters, MD
Professor
Division of Endocrinology
Keck School of Medicine
Director
Clinical Diabetes Program
University of Southern California
Los Angeles, California
John A. Romley, PhD
Research Assistant Professor
Price School of Public Policy
University of Southern California
Los Angeles, California
Disclosures
These faculty report relationships with the following organizations:
Jennie H. Best, PhD
Employee and stock ownership: Amylin Pharmaceuticals, Inc
Ryan M. Conrad, PhD
Consultant: Amylin Pharmaceuticals, Inc
Dana P. Goldman, PhD
Consultant: Amylin Pharmaceuticals, Inc
Anne L. Peters, MD
Consultant: Amylin Pharmaceuticals, Inc, Boehringer Ingelheim, CellNovo, Lilly, Novo Nordisk, sanofi-aventis
Honoraria: Dexcom, Medtronic MiniMed, Merck, Medscape, Perrigo
Speakers’ bureau: Amylin Pharmaceuticals, Inc, Takeda, Lilly, Novo Nordisk
John A. Romley, PhD
Consultant: Amylin Pharmaceuticals, Inc
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.
